Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32(6):525–31.
CAS
Article
PubMed
Google Scholar
Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009;27(11):903–17.
Article
PubMed
PubMed Central
Google Scholar
Glassman A, Canon O, Silverman R. How to get cost-effectiveness analysis right? The case of vaccine economics in Latin America. Value Health. 2016;19(8):913–20.
Article
PubMed
PubMed Central
Google Scholar
Makinen M, Kaddar M, Molldrem V, Wilson L. New vaccine adoption in lower-middle-income countries. Health Policy Plan. 2012;27(Suppl. 2):ii39–49.
Hoffmann C, Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making: a European survey. The EUROMET Group. Health Policy. 2000;52(3):179–92.
CAS
Article
PubMed
Google Scholar
Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy. 2016;14(3):245–52.
Article
PubMed
PubMed Central
Google Scholar
Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609–21.
CAS
Article
PubMed
Google Scholar
Carroll S, García Rojas AJ, Glenngård AH, Marin C. Vaccination: short- to long-term benefits from investment. J Mark Access Health Policy. 2015;12:3.
Google Scholar
Garattini L, van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ. 2011;12(6):499–502.
Article
PubMed
Google Scholar
Nuijten MJ, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. Eur J Health Econ. 2011;12(3):231–41.
CAS
Article
PubMed
Google Scholar
Ngcobo NJ, Cameron NA. The decision making process on new vaccines introduction in South Africa. Vaccine. 2012;30(Suppl. 3):C9–13.
Article
PubMed
Google Scholar
Mori AT, Norheim OF, Robberstad B. Budget impact analysis of using dihydroartemisinin-piperaquine to treat uncomplicated malaria in children in Tanzania. Pharmacoeconomics. 2016;34(3):303–14.
Article
PubMed
Google Scholar
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24.
Article
PubMed
Google Scholar
Orlewska E, Gulacsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27(10):807–27.
Article
PubMed
Google Scholar
Aballea S, Millier A, Quilici S, et al. A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother. 2013;9(6):1272–88.
Article
PubMed
PubMed Central
Google Scholar
Mauskopf J. Prevalence-based economic evaluation. Value Health. 1998;1(4):251–9.
CAS
Article
PubMed
Google Scholar
Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices: budget impact analysis. Value Health. 2007;10(5):336–47.
Article
PubMed
Google Scholar
Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14.
Article
PubMed
Google Scholar
Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016;34(11):1111–31.
Article
PubMed
Google Scholar
Drummond M, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015. p. 42–44
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16:e1–5.
Article
PubMed
Google Scholar
Patented Medicine Prices Review Board. Budget impact analysis guidelines: guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. 2007. http://www.pmprb-cepmb.gc.ca/cmfiles/bia-may0738lvv-5282007-5906.pdf. Accessed 9 Sept 2017.
Médecins Sans Frontières. The right shot: bringing down barriers to affordable and adapted vaccines. 2nd ed. 2015. http://cdn.doctorswithoutborders.org/sites/usa/files/attachments/the_right_shot_2nd_edition.pdf. Accessed 9 Sept 2017.
Brenzel L. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in Gavi eligible countries? Vaccine. 2015;33(Suppl. 1):A93–8.
Article
PubMed
Google Scholar
Haakenstad A, Birger M, Singh L, et al. Vaccine assistance to low- and middle-income countries increased to $3.6 billion In 2014. Health Aff (Millwood). 2016;35(2):242–9.
Article
Google Scholar
Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):357–71.
Article
PubMed
Google Scholar
World Health Organization. WHO position paper, January 2013. Wkly Epidemiol Rec. 2013;5:49–64.
Google Scholar
Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, World Health Organization-Coordinated Global Rotavirus Surveillance Network. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62(Suppl. 2):S96–105.
Article
PubMed
Google Scholar
Tu HA, Woerdenbag HJ, Kane S, et al. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines. 2011;10(7):1037–51.
Article
PubMed
Google Scholar
The World Bank. World Bank analytical classifications, country analytical history (Atlas methodology). http://siteresources.worldbank.org/DATASTATISTICS/Resources/OGHIST.xls. Accessed 9 Sept 2017.
The Cochrane Collaboration. Cochrane 2012 LMIC filters. 6 November 2015. Available from: http://epoc.cochrane.org/lmic-filters. Accessed 5 Sept 2017.
Cost-Effectiveness Analysis Registry. Available from: http://healtheconomics.tuftsmedicalcenter.org/cear4/Home.aspx. Accessed 5 Sept 2017.
Rheingans R, Amaya M, Anderson JD, Chakraborty P, Atem J. Systematic review of the economic value of diarrheal vaccines. Hum Vaccin Immunother. 2014;10(6):1582–94.
Article
PubMed
PubMed Central
Google Scholar
Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine. 2012;31(1):96–108.
Article
PubMed
Google Scholar
Thiboonboon K, Santatiwongchai B, Chantarastapornchit V, Rattanavipapong W, Teerawattananon Y. A systematic review of economic evaluation methodologies between resource-limited and resource-rich countries: a case of rotavirus vaccines. Appl Health Econ Health Policy. 2016;14(6):659–72.
Article
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Article
PubMed
PubMed Central
Google Scholar
Muangchana C, Riewpaiboon A, Jiamsiri S, Thamapornpilas P, Warinsatian P. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand. Vaccine. 2012;30(18):2839–47.
Article
PubMed
Google Scholar
Jit M, Yuzbashyan R, Sahakyan G, Avagyan T, Mosina L. The cost-effectiveness of rotavirus vaccination in Armenia. Vaccine. 2011;29(48):9104–11.
Article
PubMed
Google Scholar
Centenari C, Gurgel RQ, Bohland AK, Oliveira DM, Faragher B, Cuevas LE. Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings? Vaccine. 2010;28:4162–8.
Article
PubMed
Google Scholar
Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in Gavi-eligible countries. BMC Public Health. 2010;10:253.
Article
PubMed
PubMed Central
Google Scholar
Suwantika AA, Postma MJ. Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia. BMC Public Health. 2013;13:1106.
Article
PubMed
PubMed Central
Google Scholar
Suwantika AA, Tu HA, Postma MJ. Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. Vaccine. 2013;31(32):3300–7.
Article
PubMed
Google Scholar
Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005;5(1):65–79.
Article
PubMed
Google Scholar
van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014;12(1):33–40.
Article
PubMed
Google Scholar
World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. Geneva: World Health Organization; 2014.
Google Scholar
World Health Organization. Guidance for the development of evidence-based vaccination-related recommendations. Strategic Advisory Group of Experts on Immunization. Geneva: World Health Organization; 2017.
Google Scholar
Jauregui B, Janusz CB, Clark AD, et al. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions. Vaccine. 2015;33(Suppl. 1):A21–7.
Article
PubMed
Google Scholar
NICE International. The Gates reference case: what it is, why it’s important, and how to use it. Bill and Melinda Gates Foundation Methods for Economic Evaluation Project. 2014. Bill and Melinda Gates Foundation, NICE International, the Health Intervention and Technology Assessment Program (Thailand), and The University of York, Centre for Health Economics. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-International/projects/Gates-Referencecase-what-it-is-how-to-use-it.pdf. Accessed 9 Sept 2017.